Vilanterol free base | CAS# 503068-34-6 | beta-2 agonist

MedKoo Cat#: 576084 | Name: Vilanterol free base

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vilanterol, also known as GW-642444, is a long-acting beta-2 agonist. It selectively induces cAMP accumulation in CHO cells expressing the β2-AR over the β1- and β3-ARs (EC50s = 0.4, 398, and 794 nM for the human receptors, respectively). Vilanterol inhibits contractions induced by electrical stimulation in isolated superfused guinea pig trachea strips. It inhibits bronchospasms induced by histamine. Formulations containing vilanterol, in combination with fluticasone, have been used in the treatment of chronic obstructive pulmonary disease (COPD) and asthma.

Chemical Structure

Vilanterol free base

CAS#503068-34-6 (free base)

Theoretical Analysis

MedKoo Cat#: 576084

Name: Vilanterol free base

CAS#: 503068-34-6 (free base)

Chemical Formula: C24H33Cl2NO5

Exact Mass: 485.1736

Molecular Weight: 486.43

Elemental Analysis: C, 59.26; H, 6.84; Cl, 14.58; N, 2.88; O, 16.45

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 450.00	2 Weeks
10mg	USD 650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

503070-58-4 (trifenatate) 503068-34-6 (free base) 503068-35-7 (acetate)

Synonym

GW 642444; GW642444; GW-642444; Vilanterol

IUPAC/Chemical Name

(R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol

InChi Key

DAFYYTQWSAWIGS-DEOSSOPVSA-N

InChi Code

InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1

SMILES Code

ClC1=C(COCCOCCCCCCNC[C@H](O)C2=CC=C(O)C(CO)=C2)C(Cl)=CC=C1

Appearance

A solution in ethanol

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, DMF, Ethanol

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	Soluble in DMSO	0.0	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 486.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Braido F, Vlachaki I, Nikolaidis GF, Tzelis D, Barouma I, Piraino A, Madoni A, Scichilone N. Single inhaler with beclometasone, formoterol, and glycopyrronium versus triple therapies in adults with uncontrolled asthma: a systematic review and meta-analysis. Sci Rep. 2025 Feb 4;15(1):4191. doi: 10.1038/s41598-025-88374-w. PMID: 39905183. 2: Gupta S, Desai S. Green Approach for Simultaneous Determination of Long Acting β-Agonists, their Organic Counterparts and Corticosteroids by HPLC Coupled with PDA Detector. Ann Pharm Fr. 2025 Jan 28:S0003-4509(25)00009-4. doi: 10.1016/j.pharma.2025.01.009. Epub ahead of print. PMID: 39884425. 3: Tagaya E, Shinada J, Nagase H, Terada-Hirashima J, Hojo M, Sugihara N, Yagi O, Tsuji M, Akaba T, Masaki K, Fukunaga K, Ohbayashi H, Chiba K, Hozawa S, Atsuta R, Aoki Y, Hiranuma H, Gon Y, Tanaka A. The efficacy and safety of Fluticasone Furoate/Umeclidinium/vilanterol (FF/UMEC/VI) on cough symptoms in adult patients with asthma, a randomized double-blind, placebo-controlled, parallel group study: Chronic Cough in Asthma (COCOA) study. J Asthma. 2025 Feb 3:1-11. doi: 10.1080/02770903.2025.2455416. Epub ahead of print. PMID: 39874464. 4: Settipane RA, Germain G, Laliberté F, Mahendran M, Hilts A, Duh MS, Paczkowski R, Burrows E. Retrospective Cohort Study of Elderly Users of Single- or Multiple-Inhaler Triple Therapy for the Treatment of Asthma in the USA. Pulm Ther. 2025 Jan 27. doi: 10.1007/s41030-024-00285-9. Epub ahead of print. PMID: 39869154. 5: Ruan Z, Wang C, Yuan S, Fan Y, Xu B, Cong X, Li D, Miao Q. High-risk adverse events in two types of single inhaler triple-therapy: a pharmacovigilance study based on the FAERS database. Front Pharmacol. 2025 Jan 9;15:1460407. doi: 10.3389/fphar.2024.1460407. PMID: 39850558; PMCID: PMC11754260. 6: Feldman WB, Suissa S, Kesselheim AS, Avorn J, Russo M, Schneeweiss S, Wang SV. Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study. BMJ. 2024 Dec 30;387:e080409. doi: 10.1136/bmj-2024-080409. PMID: 39797646; PMCID: PMC11684032. 7: Mohamed MA, Awadalla MKA, Mohamed MS, Elsaman T, Eltayib EM. Repurposing FDA- Approved Drugs for Eumycetoma Treatment: Homology Modeling and Computational Screening of CYP51 Inhibitors. Int J Mol Sci. 2025 Jan 1;26(1):315. doi: 10.3390/ijms26010315. PMID: 39796172; PMCID: PMC11720416. 8: Cano-Salas MC, Miguel-Reyes JL, López-Estrada EC, Salas-Hernández J, Arroyo- Rojas ME, Castañeda-Valdivia M, Escobar-Preciado M, Garcés-Flores H, Guzmán- Vázquez S, García-García SR, Soto-Molina H. Cost-effectiveness of budesonide- formoterol in maintenance therapy of asthma patients. Rev Alerg Mex. 2024 Dec 23;71(4):218-228. English. doi: 10.29262/ram.v71i4.1295. PMID: 39752263. 9: Mannino D, Weng S, Germain G, Boudreau J, Tardif-Samson A, Forero- Schwanhaeuser S, Laliberté F, Gravelle P, Compton CH, Noorduyn SG, Paczkowski R. Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease. Adv Ther. 2025 Feb;42(2):1131-1146. doi: 10.1007/s12325-024-03088-1. Epub 2024 Dec 28. PMID: 39731707; PMCID: PMC11787206. 10: Shah CH, Reed RM, Wastila L, Onukwugha E, Gopalakrishnan M, Zafari Z. Comparative effectiveness of olodaterol/tiotropium and vilanterol/umeclidinium among COPD patients: a high-dimensional propensity score matched new user cohort study in a US medicare population. Expert Rev Respir Med. 2024 Dec;18(12):1113-1120. doi: 10.1080/17476348.2024.2446598. Epub 2024 Dec 30. PMID: 39718113. 11: Baptist AP, Germain G, Klimek J, Laliberté F, Schell RC, Forero- Schwanhaeuser S, Moore A, Noorduyn SG, Paczkowski R. Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI). Adv Ther. 2025 Feb;42(2):1061-1074. doi: 10.1007/s12325-024-03083-6. Epub 2024 Dec 23. PMID: 39714547; PMCID: PMC11787182. 12: Zhu H, Lei J, Gao F, Guo Y, Zhao L. Evaluation of comparative efficacy of Umeclidinium/Vilanterol versus other bronchodilators in the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of RCTs. BMC Pulm Med. 2024 Dec 18;24(1):609. doi: 10.1186/s12890-024-03445-4. PMID: 39696097; PMCID: PMC11654331. 13: Young C, Lee LY, DiRocco KK, Germain G, Klimek J, Laliberté F, Lejeune D, Noorduyn SG, Paczkowski R. Adherence and Persistence with Single-Inhaler Triple Therapy Among Patients with COPD Using Commercial and Medicare Advantage US Health Plan Claims Data. Adv Ther. 2025 Feb;42(2):830-848. doi: 10.1007/s12325-024-03055-w. Epub 2024 Dec 5. PMID: 39636563; PMCID: PMC11787229. 14: Jokšaitė S, Wood R, Ismaila A, Camidge L, Mizukami A, Czira A, Massey O, Yarita M, Compton C, Siddiqui R, Jennison T, Ishii T, Hashimoto K, Rothnie KJ. Comparative adherence and persistence of single-inhaler and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in Japan: a retrospective cohort study. BMJ Open. 2024 Dec 4;14(12):e080864. doi: 10.1136/bmjopen-2023-080864. PMID: 39632104; PMCID: PMC11624741. 15: Zhou R, Qin Y, Hu S, Xu Y, Feng C. Effect of dual bronchodilators plus preoperative rehabilitation in operable LC & chronic obstructive pulmonary disease. Future Oncol. 2024 Dec;20(40):3471-3476. doi: 10.1080/14796694.2024.2430164. Epub 2024 Nov 28. PMID: 39607005; PMCID: PMC11776851. 16: Ramírez-Venegas A, Montiel-Lopez F, Robles-Hernández RE, Celli BR, Sansores RH, Cassou-Martínez M, Lara-Albisua JLP, González-González C, Mayar-Maya ME, Hernández-Morales AP, Hernández-Zenteno RJ, Falfán-Valencia R, Thirión-Romero I, Pérez-Bautista O, Pérez-Padilla R. Effectiveness of ICS/LABA and LAMA/LABA in COPD due to biomass. ERJ Open Res. 2024 Nov 25;10(6):00154-2024. doi: 10.1183/23120541.00154-2024. PMID: 39588082; PMCID: PMC11587136. 17: Comparison chart: Some inhaled drugs for treatment of asthma. Med Lett Drugs Ther. 2024 Nov 25;66(1716):e192-e195. doi: 10.58347/tml.2024.1716b. PMID: 39558441. 18: Drugs for asthma. Med Lett Drugs Ther. 2024 Nov 25;66(1716):185-192. doi: 10.58347/tml.2024.1716a. PMID: 39558440. 19: Yoshinoya K, Watanabe S, Nakazima S, Honda H, Harada Y, Kudo K, Okuda M, Ohshima S. [A CASE OF IgG4-RELATED DISEASE WITH CONFIRMED RESPONSE TO DUPILUMAB BY SMALL SALIVARY GLAND BIOPSY]. Arerugi. 2024;73(9):1158-1162. Japanese. doi: 10.15036/arerugi.73.1158. PMID: 39551504. 20: Alberola AH, Nogal NB, Miranda AB, Lipson DA, Tombs L, Han MK. The Effect of Patient Sex on Treatment Outcomes in COPD: A Post Hoc Analysis of the IMPACT Trial. Chronic Obstr Pulm Dis. 2024 Nov 22;11(6):591-603. doi: 10.15326/jcopdf.2024.0541. PMID: 39531369; PMCID: PMC11703016.